<DOC>
	<DOCNO>NCT01639846</DOCNO>
	<brief_summary>To purpose study establish efficacy safety RX-10045 ophthalmic solution alleviate sign symptom allergic conjunctivitis</brief_summary>
	<brief_title>Evaluation Onset Duration Action RX-10045 Allergic Conjunctivitis</brief_title>
	<detailed_description>Allergies relatively common among general population . Ocular sign symptom include itch , discomfort , redness , chemosis , tear , eyelid swelling . Allergic reaction vary mild , self-limiting disease , debilitate condition significantly impair quality life allergen-sensitive individual . Currently approve treatment ocular allergy reduce sign symptom early phase reaction ; however , evidence suggest many patient suffer persistent late phase reaction . Manifestations late phase reaction occur 6 24 hour allergen exposure characterize influx acute inflammatory cell conjunctivae . Administration anti-inflammatory agent decrease allergy sign symptom early late phase reaction . RX-10045 show efficacious multiple pre-clinical dry eye disease model pre-clinical model allergic conjunctivitis . The objective clinical study ass safety efficacy RX-10045 ophthalmic solution treatment sign symptom allergic conjunctivitis induce Conjunctival Allergen Challenge Model allergic conjunctivitis 15 minute 8 hour medication instillation . It anticipate RX-10045 therapeutic potential treatment allergic conjunctivitis acceptable risk-benefit profile .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects MUST : 1 . Have positive history ocular allergy 2 . Have positive bilateral conjunctival allergen challenge ( CAC ) reaction Subjects MUST NOT : 1 . Have know contraindication sensitivity study medication component 2 . Have ocular condition , opinion investigator , could affect subject 's safety trial parameter 3 . Use disallowed medication period indicate prior enrollment study 4 . Be female currently pregnant , plan pregnancy , lactating , use medically acceptable form birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>